Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | HLX07 |
Synonyms | |
Therapy Description |
HLX07 (pimurutamab) is a humanized monoclonal antibody directed against EGFR, which was demonstrated to have increased affinity for Egfr compared to cetuximab and may result in antitumor activity (PMID: 33713216). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
HLX07 | HLX-07|HLX 07|Pimurutamab | EGFR Antibody 60 | HLX07 (pimurutamab) is a humanized monoclonal antibody directed against EGFR, which was demonstrated to have increased affinity for Egfr compared to cetuximab and may result in antitumor activity (PMID: 33713216). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02648490 | Phase I | Acetaminophen + Dexamethasone + Diphenhydramine + Ondansetron HLX07 | An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of HLX07,in Patients With Advanced Solid Cancers | Completed | USA | 1 |